Cargando…

Circulating Tumor DNA Detection in the Management of Anti-EGFR Therapy for Advanced Colorectal Cancer

Background: Anti-EGFR antibodies are a standard care for advanced KRAS-wild type colorectal cancers. Circulating tumor DNA (ctDNA) monitoring during therapy can detect emergence of KRAS mutant clones and early resistance to therapy. Case Presentation: We describe a 61-years-old man presenting a meta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Knebel, Franciele H., Bettoni, Fabiana, da Fonseca, Leonardo G., Camargo, Anamaria A., Sabbaga, Jorge, Jardim, Denis L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439419/ https://www.ncbi.nlm.nih.gov/pubmed/30967998 http://dx.doi.org/10.3389/fonc.2019.00170

Ejemplares similares

Circulating Tumour DNA Sequencing Identifies a Genetic Resistance-Gap in Colorectal Cancers with Acquired Resistance to EGFR-Antibodies and Chemotherapy
por: Knebel, Franciele H., et al.
Publicado: (2020)

Longitudinal Circulating Tumor DNA Profiling in Metastatic Colorectal Cancer During Anti-EGFR Therapy
por: Yang, Wentao, et al.
Publicado: (2022)

Corrigendum: Longitudinal Circulating Tumor DNA Profiling in Metastatic Colorectal Cancer During Anti-EGFR Therapy
por: Yang, Wentao, et al.
Publicado: (2022)

Case Report: Longitudinal monitoring of clonal evolution by circulating tumor DNA for resistance to anti-EGFR antibody in a case of metastatic colorectal cancer
por: Sagawa, Tamotsu, et al.
Publicado: (2023)

Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient
por: Ribeiro, Maurício Fernando Silva Almeida, et al.
Publicado: (2021)

The Effects of Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer—The Impact in Intratumoral Heterogeneity
por: Bettoni, Fabiana, et al.
Publicado: (2019)

Current concepts of anti-EGFR targeting in metastatic colorectal cancer
por: Doleschal, Bernhard, et al.
Publicado: (2022)

The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation
por: Carpinetti, Paola, et al.
Publicado: (2015)

Circulating Tumor DNA in Identifying Resistant Sub-Clones Post EGFR Blockade: Implications for EGFR Rechallenge
por: Chennamadhavuni, Adithya, et al.
Publicado: (2022)

Non-Coding RNAs Regulate the Resistance to Anti-EGFR Therapy in Colorectal Cancer
por: Chu, Jinjin, et al.
Publicado: (2022)

Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer
por: Cremolini, Chiara, et al.
Publicado: (2023)

Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer
por: Fakih, M., et al.
Publicado: (2010)

KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies
por: Soulières, D., et al.
Publicado: (2010)

Combination of Anti-EGFR and Anti-VEGF Drugs for the Treatment of Previously Treated Metastatic Colorectal Cancer: A Case Report and Literature Review
por: Li, Yong, et al.
Publicado: (2021)

Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board
por: Xavier, Camila B, et al.
Publicado: (2023)

High Circulating Sonic Hedgehog Protein Is Associated With Poor Outcome in EGFR-Mutated Advanced NSCLC Treated With Tyrosine Kinase Inhibitors
por: Takam Kamga, Paul, et al.
Publicado: (2021)

Corrigendum: High Circulating Sonic Hedgehog Protein Is Associated With Poor Outcome in EGFR-Mutated Advanced NSCLC Treated With Tyrosine Kinase Inhibitors
por: Takam Kamga, Paul, et al.
Publicado: (2022)

Circulating Tumor DNA Is Capable of Monitoring the Therapeutic Response and Resistance in Advanced Colorectal Cancer Patients Undergoing Combined Target and Chemotherapy
por: Cao, Hua, et al.
Publicado: (2020)

Dynamic cfDNA Analysis by NGS in EGFR T790M-Positive Advanced NSCLC Patients Failed to the First-Generation EGFR-TKIs
por: Ma, Li, et al.
Publicado: (2021)

Efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma
por: Marta, Guilherme Nader, et al.
Publicado: (2021)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
por: Li, Xingyuan, et al.
Publicado: (2023)

Clinical Utility of Circulating Tumor DNA in Advanced Rare Cancers
por: Okuma, Hitomi Sumiyoshi, et al.
Publicado: (2021)

Choice of 16S Ribosomal RNA Primers Impacts Male Urinary Microbiota Profiling
por: Heidrich, Vitor, et al.
Publicado: (2022)

The short-term efficacy and safety of induction chemotherapy combined with PD-1 inhibitor or anti-EGFR in locoregionally advanced nasopharyngeal carcinoma
por: Xiang, Xiaoyong, et al.
Publicado: (2023)

Editorial: Advances in genetics and molecular diagnosis in colorectal cancer
por: Islam, Farhadul, et al.
Publicado: (2023)

Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma
por: Padfield, Emily, et al.
Publicado: (2015)

Circulating tumor DNA sequencing in colorectal cancer patients treated with first-line chemotherapy with anti-EGFR
por: Lim, Yoojoo, et al.
Publicado: (2021)

STRA6 Polymorphisms Are Associated With EGFR Mutations in Locally-Advanced and Metastatic Non-Small Cell Lung Cancer Patients
por: Muñiz-Hernández, Saé, et al.
Publicado: (2020)

Assessing the Impact of Circulating Tumor DNA (ctDNA) in Patients With Colorectal Cancer: Separating Fact From Fiction
por: Gabriel, Emmanuel, et al.
Publicado: (2018)

Tumor genomic profiling and personalized tracking of circulating tumor DNA in Vietnamese colorectal cancer patients
por: Nguyen, Huu Thinh, et al.
Publicado: (2022)

Case Report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer
por: Mauri, Gianluca, et al.
Publicado: (2022)

Efficacy of EGFR-TKI Plus Chemotherapy or Monotherapy as First-Line Treatment for Advanced EGFR-Mutant Lung Adenocarcinoma Patients With Co-Mutations
por: Yang, Zhengyu, et al.
Publicado: (2021)

LAPS score for individualized treatment of advanced EGFR-mutated non-small cell lung cancer receiving EGFR-TKIs with or without bevacizumab
por: Wu, Yahua, et al.
Publicado: (2023)

Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study
por: Parisi, Alessandro, et al.
Publicado: (2021)

Acute Acalculous Cholecystitis in a Patient with Metastatic Renal Cell Carcinoma Treated with Sunitinib
por: da Fonseca, Leonardo Gomes, et al.
Publicado: (2014)

Five Technologies for Detecting the EGFR T790M Mutation in the Circulating Cell-Free DNA of Patients With Non-small Cell Lung Cancer: A Comparison
por: Chen, Yi-Lin, et al.
Publicado: (2019)

Radiomics Signature as a Predictive Factor for EGFR Mutations in Advanced Lung Adenocarcinoma
por: Hong, Duo, et al.
Publicado: (2020)

Corrigendum: Case report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer
por: Mauri, Gianluca, et al.
Publicado: (2023)

EGFR DNA Methylation Correlates With EGFR Expression, Immune Cell Infiltration, and Overall Survival in Lung Adenocarcinoma
por: Xu, Zhanyu, et al.
Publicado: (2021)

First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Wu, Qiang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_19gje170n2ls2eqh7sgq6g3jqq